| Assessment Status | Rapid Review complete |
| HTA ID | 24017 |
| Drug | Alectinib |
| Brand | Alecensa® |
| Indication | As adjuvant treatment following complete tumour resection for adult patients with ALK-positive NSCLC at high risk of recurrence. |
| Assessment Process | |
| Rapid review commissioned | 24/05/2024 |
| Rapid review completed | 02/07/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of alectinib for this indication compared with the current standard-of-care, on the basis of the proposed price relative to currently available therapies. |
